Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
FDA approves Pfizer's BRAFTOVI (encorafenib) with cetuximab and mFOLFOX6 for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. Based on BREAKWATER trial, the combination showed significant improvement in response rate and durability. This is the first BRAF-targeted therapy regimen for first-line treatment of BRAF V600E-mutant mCRC.
The OncFive: Top Oncology Articles for the Week of 12/15
FDA approves encorafenib combo for BRAF V600E+ metastatic CRC, ensartinib for ALK+ NSCLC, issues CRL to subcutaneous amivantamab BLA in EGFR+ NSCLC, seeks EU approval for ibrutinib plus R-CHOP in frontline MCL, and grants breakthrough therapy designation to sacituzumab govitecan for second-line ES-SCLC.
Related Clinical Trials:
FDA Approves Braftovi Plus Erbitux and Chemo for Metastatic Colorectal Cancer Subset
The FDA approved Braftovi plus Erbitux and mFOLFOX6 for treating metastatic colorectal cancer with a BRAF V600E mutation, based on the BREAKWATER trial. The regimen showed a 61% objective response rate compared to 40% in the control arm. Common side effects included nausea, peripheral neuropathy, and decreased neutrophil counts.
Pancreatic Cancer: A Look Back at 2024
2024 saw progress in pancreatic cancer treatment with four new drug approvals, a phase 3 trial showing survival benefits, and the first phase 3 RAS inhibitor trial. The five-year survival rate rose to 13%, though pancreatic cancer remains challenging. Targeted therapies and biomarker testing are crucial, with new options like NALIRIFOX, KRAS inhibitors, and TTFields offering hope.
Intermittent or Continuous Panitumumab Plus FOLFIRI in First-Line Treatment of RAS and
Intermittent panitumumab and FOLFIRI showed promising progression-free survival in RAS/BRAF wild-type metastatic colorectal cancer patients, with median progression-free survival of 11.2 months (continuous) and 17.5 months (intermittent). The intermittent approach reduced toxicity and allowed more time off treatment.
Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic
The TOPGEAR trial found that adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates and tumor downstaging in resectable gastric cancer patients but does not extend overall survival. The study showed no significant difference in 5-year overall survival or progression-free survival between the chemoradiation and chemotherapy-alone arms, with similar rates of toxicity and surgical complications.
Toxoplasmosis Treatment Drugs Market Size, Growth Demand And Share Analysis 2033
The toxoplasmosis treatment drugs market is projected to grow from $3.16 billion in 2023 to $4.18 billion by 2028, driven by rising prevalence, product innovations, and increased healthcare expenditure.
Breakthrough immunotherapy drug revolutionizes pancreatic cancer treatment
Pancreatic ductal adenocarcinoma (PDAC) has a 11% survival rate due to its immunosuppressive tumor microenvironment (TME). Recent breakthroughs reveal NKT cells and type-I interferon (IFN) as key players in overcoming PDAC's defenses. Folinic acid, a chemotherapy supplement, boosts NKT cells and type-I IFN, allowing immune cells to infiltrate and attack PDAC tumors in mice, extending survival and improving anti-PD-1 therapy effectiveness. This research, if translated to humans, could transform immunotherapy outcomes for PDAC and other 'cold' tumors.
CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC
CM24 plus nivolumab and SOC chemotherapy improved OS (7.92 vs 5.55 months), PFS (3.9 vs 2.0 months), ORR (25% vs 7%), and DCR (63% vs 47%) in metastatic PDAC patients compared to SOC chemotherapy alone. CM24, a multi-functional antibody blocking CEACAM1, showed enhanced efficacy in biomarker-enriched populations, prompting further investigation in a phase 2b study targeting multiple indications.
Related Clinical Trials:
Locoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Meta-analysis of 40 RCTs (11,576 patients) shows surgical-based locoregional therapies (LRTs) for nonmetastatic hepatocellular carcinoma (HCC) yield best outcomes; embolization-based LRTs poorer. Hierarchical efficacy observed: surgery with adjuvant therapy > surgery alone > radiofrequency ablation (RFA) > microwave ablation (MWA) and radiotherapy (RT) > hepatic arterial infusion chemotherapy (HAIC) > transarterial chemoembolization (TACE) > transarterial radioembolization (TARE) and transarterial bland embolization (TAE). Findings suggest LRT remains crucial in HCC treatment, with some forms preferred over others.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath